Unadjusted and adjusted HRs for anticoagulation outcomes in patients with VKORC1 G/A or A/A and CYP2C9 variant genotype
| Genotype and outcome . | Unadjusted . | Adjusted . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| VKORC1 G/A genotype* | ||||
| Time to first therapeutic INR | 0.79 (0.50-1.25) | .32 | 0.62 (0.27-1.39) | .24 |
| Time to first above-range INR | 0.71 (0.32-1.59) | .40 | 0.58 (0.11-3.19) | .53 |
| Time to stable anticoagulation | 1.03 (0.65-1.63) | .91 | 1.11 (0.64-1.90) | .72 |
| VKORC1 A/A genotype* | ||||
| Time to first therapeutic INR | 0.87 (0.55-1.37) | .54 | 0.76 (0.34-1.57) | .43 |
| Time to first above-range INR | 0.70 (0.32-1.56) | .39 | 0.56 (0.14-3.15) | .60 |
| Time to stable anticoagulation | 0.69 (0.43-1.10) | .12 | 0.8 (0.47-1.37) | .41 |
| CYP2C9 variant genotype† | ||||
| Time to first therapeutic INR | 0.85 (0.61-1.19) | .34 | 1.04 (0.69-1.57) | .86 |
| Time to first above-range INR | 1.02 (0.53-1.94) | .96 | 0.91 (0.43-1.92) | .81 |
| Time to stable anticoagulation | 1.17 (0.83-1.65) | .38 | 0.88 (0.60-1.29) | .51 |
| Genotype and outcome . | Unadjusted . | Adjusted . | ||
|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | |
| VKORC1 G/A genotype* | ||||
| Time to first therapeutic INR | 0.79 (0.50-1.25) | .32 | 0.62 (0.27-1.39) | .24 |
| Time to first above-range INR | 0.71 (0.32-1.59) | .40 | 0.58 (0.11-3.19) | .53 |
| Time to stable anticoagulation | 1.03 (0.65-1.63) | .91 | 1.11 (0.64-1.90) | .72 |
| VKORC1 A/A genotype* | ||||
| Time to first therapeutic INR | 0.87 (0.55-1.37) | .54 | 0.76 (0.34-1.57) | .43 |
| Time to first above-range INR | 0.70 (0.32-1.56) | .39 | 0.56 (0.14-3.15) | .60 |
| Time to stable anticoagulation | 0.69 (0.43-1.10) | .12 | 0.8 (0.47-1.37) | .41 |
| CYP2C9 variant genotype† | ||||
| Time to first therapeutic INR | 0.85 (0.61-1.19) | .34 | 1.04 (0.69-1.57) | .86 |
| Time to first above-range INR | 1.02 (0.53-1.94) | .96 | 0.91 (0.43-1.92) | .81 |
| Time to stable anticoagulation | 1.17 (0.83-1.65) | .38 | 0.88 (0.60-1.29) | .51 |
All Cox regression models were adjusted for age, sex, weight, warfarin dose, indication for therapy, cohort, and VKORC1, CYP2C9, and CYP4F2 genotype.
Survival function was compared with VKORC1 wild-type G/G genotype group.